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Mutations in the gene encoding superoxide dismutase 1 (SOD1) account for about 20% of the cases of familial
amyotrophic lateral sclerosis (fALS). It is well established that mutations in SOD1, associated with fALS, heighten the
propensity of the protein to misfold and aggregate. Although aggregation appears to be a factor in the toxicity of
mutant SOD1s, the precise nature of this toxicity has not been elucidated. A number of other studies have now
firmly established that raising the levels of wild-type (WT) human SOD1 (hSOD1) proteins can in some manner
augment the toxicity of mutant hSOD1 proteins. However, a recent study demonstrated that raising the levels of
WT-hSOD1 did not affect disease in mice that harbor a mouse Sod1 gene (mSod1) encoding a well characterized
fALS mutation (G86R). In the present study, we sought a potential explanation for the differing effects with
WT-hSOD1 on the toxicity of mutant hSOD1 versus mutant mSod1. In the cell culture models used here,
we observe poor interactions between WT-hSOD1 and misfolded G86R-mSod1, possibly explaining why
over-expression of WT-hSOD1 does not synergize with mutant mSod1 to accelerate the course of the disease in mice.Introduction
Mutations in the gene encoding superoxide dismutase 1
(SOD1) account for about 20% of the cases of familial
amyotrophic lateral sclerosis (fALS) {http://alsod.iop.kcl.
ac.uk/default.aspx}. The SOD1 protein is a relatively small
antioxidant enzyme comprised of 153 amino acids. In its
active state, the protein dimerizes to form the mature en-
zyme with each subunit binding 1 atom of Zn and 1 atom
of Cu [1-3]. To date more than 165 mutations in more
than half of the amino acid residues in the enzyme have
been identified in patients diagnosed with fALS {http://
alsod.iop.kcl.ac.uk/default.aspx}. The impact of these mu-
tations on its enzymatic activity varies greatly, and it has
not yet been possible to define a single mechanism by
which these mutations cause disease [for review see [4].
One common feature of mutant SOD1 proteins is that
they exhibit a high tendency to aggregate aberrantly into* Correspondence: drb1@ufl.edu
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reproduction in any medium, provided the orhigh molecular weight structures, which can be isolated
biochemically due to their insolubility in non-ionic deter-
gents [5].
Although aggregation of mutant SOD1 is by some man-
ner linked to the toxic property of the protein that is re-
sponsible for inducing motor neuron disease, the nature of
the toxic property remains incompletely defined and may
be multifactorial [4]. One of the more interesting avenues
towards improving our understanding of the basis of mu-
tant SOD1 toxicity has been revealed in studies in which
mice expressing mutant SOD1 have been mated to mice
expressing wild-type hSOD1. A number of studies have
now firmly established that raising the levels of WT-
hSOD1 proteins by crossing a strain of mice produced by
Gurney et al. (Gur WT [6]) to mutant hSOD1 mice can, in
some manner, accelerate the onset of paralysis [7-11]. Im-
portantly, the Gur WT mice express WT-hSOD1 at very
high levels and lines of WT-hSOD1 mice that express at
lower levels do not as uniformly accelerate disease [11,12].
The basis for the current work is a recent study by
Audet and colleagues that asked whether overexpression
of WT-hSOD1, using the Gur WT strain, could augment
the toxicity of G86R-mSod1, finding no effect [13]. Thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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what has been used for mice that express mutant human
proteins; a genomic DNA fragment of the mouse gene was
mutated to encode an fALS mutation. The G86R mutation
in mouse Sod1 is equivalent to the human G85R hSOD1
mutation. The difference in numbering is a consequence of
the historical numbering of human SOD1 residues based
on the mature human protein sequence (initiator methio-
nine removed post-translationally) whereas the mouse se-
quence was numbered by actual codon position. The lack
of an effect of co-expressed WT-hSOD1 on disease in the
G86R mice is not a peculiarity of the mutation because
mice generated by crossing Gur WT animals to mice ex-
pressing G85R-hSOD1 develop motor neuron disease con-
siderably earlier than mice expressing the mutant protein
alone [10]. The different outcomes in these two experi-
mental settings implies that improving our understanding
of the way WT-hSOD1 interacts with G85R hSOD1 and
G86R-mSod1 could provide insight into how the presence
of WT-hSOD1 accelerates the onset of paralysis.
To study interactions between hSOD1 and mSod1 that
may occur when fALS mutations induce misfolding,
we have employed an established cell model of mutant
SOD1 aggregation in conjunction with co-transfection ap-
proaches. Using a detergent extraction and sedimentation
assay, we examine whether WT-hSOD1 interacts with
misfolded G86R-mSod1. Additionally, to visualize such in-
teractions, and following a strategy previously described
[11,15], we have fused the SOD1 variants to fluorescent
tags; G86R-mSod1 fused to red fluorescent protein (RFP)
and WT-hSOD1 or WT-mSod1 fused yellow fluorescent
protein (YFP). Using both biochemical and visual methods
we compare the degree to which WT-mSod1 and WT-
hSOD1 interact with misfolded aggregates of G86R-mSod1.
Methods
Generation of hSOD1/mSod1 DNA expression plasmids
and split luciferase constructs
Expression plasmids (pEF.Bos [16]) that encode wild-
type (WT) hSOD1, WT-mSod1, A4V-hSOD1, and G85R-
hSOD1 have been previously described [17-19]. The
G86R mutation in mSod1 was introduced into pEF.
Bos-WT-mSod1 using oligonucleotides that encode the
desired mutation and the Quick Change mutagenesis
kit (Stratagene/Life Technologies/Thermo, Grand Island,
NY). WT-hSOD1mon and WT-mSod1mon were created
by introducing mutations at codons 50 and 51 to change
amino acids F and G at these positions to E. Mutations
were introduced in pEF.Bos vectors for WT-hSOD1 and
WT-mSod1 using oligonucleotides encoding the desired
mutations and the Quick Change Kit. pEF.Bos vectors
encoding WT-hSOD1 and G85R-hSOD1 fused to tur-
boRFP (Evrogen, Moscow, Russia) and eYFP (Invitrogen/
Life Technologies/Thermo Grand Island, NY,) have alsobeen previously described [11,15]. To create pEF.Bos ex-
pression plasmids that encode fusions of G85R-hSOD1
and G86R-mSod1 to YFP and RFP, and WT-hSOD1mon
and WT-mSod1mon fused to YFP and RFP, we started
with pEF.Bos vectors encoding WT-hSOD1:YFP or WT-
hSOD1:RFP fusions and removed the segment of the vec-
tor encoding SOD1 by digestion with unique (engineered)
Nco 1 and Sal 1 restriction endonuclease sites. We then
inserted cDNA encoding, WT-mSod1, G86R-mSod1, WT-
hSOD1mon and WT-mSod1mon engineered with com-
patible ends to produce the new vectors encoding
in-frame fusion proteins. All vectors were extensively se-
quenced to verify the presence of the desired mutations
and the absence of any unwanted mutations.
The split, humanized, Gaussia luciferase (hGluc) con-
structs (New England Biolabs, Ipswich, MA, USA) were
generated by cleaving pEF.Bos vectors encoding WT-
hSOD1 or WT-hSOD1mon with Sal1 and inserting
segments of cDNA encoding hGluc in-frame at the C-
terminus of the SOD1 cDNAs. Each hGluc segment
was amplified using standard PCR procedures with the
primers hGluc-S (cgcagctgcagtcgaccgatggtggcggtggctct)
and hGluc1-BOS-AS (tcccaggtgggtaccttagcctatgccgccctgt)
for the N-terminal segment (L1) or hGluc2-BOS-AS
(tcccaggtgggtaccttagtcaccaccggcccc) for the C-terminal
segment (L2) of luciferase. PCR products were analyzed
on a 1% agarose gel to confirm the target fragment was
amplified. In most cases a single PCR product was
present. If there were multiple PCR products, the de-
sired fragment was cut from a preparative agarose gel,
extracted, and purified using the QIAquick Gel Extraction
kit (Qiagen, Germantown, MD, USA; Cat. No 28706).
PCR products were inserted into the cleaved pEF.Bos-
SOD1 vectors using the In-Fusion Cloning kit (Clontech,
Mountain View, CA; Cat. No 639601). All plasmids were
then transformed into Stellar competent cells (Clontech) fol-
lowing standard transformation strategies. The FastPlasmid
Mini Kit (5 Prime, Gaithersburg, MD, USA; Ref# 2300010)
was used to isolate new recombinants, which were verified
by DNA sequence analysis. Upon verification of the cor-
rect plasmid DNAs, large scale preparations of the differ-
ent plasmids for transfection were prepared by standard
cesium chloride gradient purification.
Transient transfections and microscopy analyses
Expression of hSOD1/mSod1 constructs for analyses of
detergent-insolubility were performed in HEK293FT cells
as explained in figure legends and following procedures
described in previous studies [5,20]. Briefly, the expression
plasmids were transiently transfected into HEK293FT
cells. Following the times indicated (24 or 48 hrs), the cells
were harvested and subjected to detergent extraction and
sedimentation to separate soluble and insoluble forms of
SOD1. Detergent fractions were analyzed by SDS-PAGE
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proteins were visualized and quantified on a Fuji Imaging
system. Each experiment was repeated and quantified at
least 3 times.
For studies to visualize inclusions formed by YFP and
RFP fusion constructs, we transfected Chinese Hamster
Ovary (CHO) cells because these cells normally show a
very flat morphology with a distinct nucleus and cyto-
plasm; allowing for a good visualization of intracellular
inclusions. These cells also show good adherence to cul-
ture plates and resist lifting after saponin treatment.
Cells were split into 12-well plates containing Poly-L-
Lysine coated coverslips, and incubated at 37°C with 5%
CO2 for 24 hours. Cells were transiently transfected with
the vectors of interest using Lipofectamine-2000 (single
transfections: 500 ng total DNA used; Co-transfections:
500 ng of each construct used). Twenty-four hours after
transfection, one set of cells were treated with 0.1% sap-
onin in 1x PBS for 30 minutes. The cells were then
rinsed with 1x PBS, and fixed in 4% paraformaldehyde
(1x PBS). A 1:2000 solution of DAPI in 1x PBS was used
to stain nuclei. Coverslips were then mounted on slides
for analysis via fluorescence microscopy. All experiments
were performed three times, and each sample was ana-
lyzed for the presence and composition of inclusion-like
structures. Representative examples of cells from each
sample were photographed. The camera exposures used
to capture RFP and YFP images in co-transfections were
recorded and compared to single transfections to ensure
that the fluorescence was the result of the YFP, and not
bleed-through from co-expressed RFP.
For each construct analyzed, multiple transfections
were performed (at least 3) and multiple images for each
transfection experiment were captured. Between 250
and 1,000 cells expressing the fluorescent fusion protein
were assessed for each experiment, depending upon the
transfection efficiency for a particular experiment. The
images shown in the relevant figures are representative
of at least 3 individual experiments.
Luciferase assay
CHO cells were cultured into 6 well plates and transi-
ently transfected, at 90-95% confluency, with equimolar
amounts of two split luciferase constructs (total 2 μg
DNA, 1 μg per construct). Co-transfections were per-
formed using Lipofectamine 2000, following the manu-
facturer’s protocol (Invitrogen, Carlsbad, CA, USA). The
cells were incubated at 37°C in a CO2 incubator for
24 hours, rinsed with 1x PBS, harvested, and the cells
were pelleted by centrifuging at 5000 xg for 2 min. A
coelenterazine assay was used in order to demonstrate
the luciferase activity of the split luciferase constructs.
The cell pellets were resuspended in approximately 5x
estimated pellet volume in 1x PBS containing proteaseinhibitor cocktail (Sigma, St. Louis, MO; cat #P8340)
and lysed by three freeze-thaw cycles in a dry-ice/100%
alcohol solution and a 42°C water bath. The samples
were centrifuged and the supernatant was transferred to
new Eppendorf tubes. The supernatant was diluted 1:20
and 2 μl of each diluted sample was transferred to a
96-well plate. The coelenterazine assay was performed
following the manufacturer’s protocol (Nanolight Tech-
nology, Pinetop, AZ, USA; Cat. No 303–500) using a mi-
croplate reader (Synergy HT, Biotech instruments). This
assay was repeated two more times with each repeated
transfection.Statistical analyses
Data on relative aggregation propensity were analyzed
on GraphPad PRISM 5.01 Software (La Jolla, CA) to de-
termine statistical differences, using unpaired student t-
tests, and generate graphic representations.Results
WT-hSOD1 does not readily co-aggregate with G86R-
mSod1
In order to determine whether WT-hSOD1 co-aggregates
with or otherwise modulates aggregation of G86R-mSod1,
we used a cell culture model of mutant SOD1 aggregation
that we have used extensively in the past. Human embry-
onic kidney cells (HEK293FT) were transiently transfected
with the indicated mouse and human SOD1 constructs.
Forty-eight hours following transfection, cells were har-
vested and detergent-soluble (S1) and detergent-insoluble
(P2) fractions were obtained as previously described [19].
Note that the aggregation propensity of SOD1 proteins is
measured by the ratio of detergent-insoluble to detergent-
soluble SOD1. A common characteristic for both WT-
hSOD1 and WT-mSod1 proteins is their low inherent ag-
gregation propensity when expressed in cultured cells
[17,19]. As expected, expression of WT-hSOD1 in our cell
culture system induced little aggregation of this protein as
assayed by the formation of detergent insoluble complexes
(hWT, Figure 1A and B). In each experiment, expression
of the A4V variant of hSOD1 provided a positive con-
trol, which robustly aggregated (A4V, Figure 1A and B).
Compared to WT-hSOD1, G86R-mSod1 showed a much
higher tendency to aggregate (Figure 1A, P2 upper panel;
and B). At 48 hours post-transfection, cells co-expressing
WT-hSOD1 with G86R-mSod1 showed no statistically sig-
nificant decrease in the level of detergent insoluble mutant
mSod1 nor did we observe a statistically significant in-
crease in the level of insoluble WT-hSOD1 in cells ex-
pressing both proteins (Figure 1A and B). These data
suggest that WT-hSOD1 does not readily interact with
misfolded G86R-mSod1 that is organized into detergent-
insoluble complexes.
Figure 1 WT-hSOD1 does not co-sediment with aggregates formed by G86R-mSOD1. A) Immunoblot of detergent-insoluble (P2) and
soluble (S1) fractions of HEK293FT cells transfected for 48 hours with vectors for WT-hSOD1 (hWT), A4V-hSOD1 (A4V), G86R-mSod1 (G86R), or
co-transfected with 2 vectors (hWT + G86R and GFP + G86R). The GFP vector served as a co-transfection control. Note that G86R-mSod1 migrates
faster than the hSOD1 constructs as noted on right side of the Figure. B) Quantification of the relative aggregation propensity of each transfected
protein. Paired student t-tests were performed to establish significant differences with hWT: *p ≤ 0.05, #p≤ 0.005. Bars represent mean ± SEM. Note
that the aggregation propensity of WT-hSOD1 in cells co-transfected with G86R-mSod1 is not significantly greater than when expressed alone.
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Previous characterization of WT-hSOD1 fused to green
fluorescent protein (GFP) have demonstrated normal
dimerization and full activity of the SOD1 protein, and
thus fusion of SOD1 with such fluorescent reporters does
not necessarily alter the folding of SOD1 [21]. We have
previously used a strategy in which WTand mutant SOD1
was fused to either red fluorescent protein (RFP) or yellow
fluorescent protein (YFP) as a means to observe interac-
tions between the WT and mutant proteins within aggre-
gates [11,15]. We have also developed a strategy in which
cells are treated with saponin prior to fixation to distin-
guish soluble, or diffusible, molecules from insoluble, or
immobile, molecules. Saponin is an amphipathic glycoside
that creates holes in the plasma membrane without lysing
the cell [for review see [22]. Fusions of WT-hSOD1 to
YFP are diffusely distributed throughout the cytosol and
readily diffuse out of cells permeabilized with saponin;
properties consistent with fully soluble proteins [15,23].
Unlike the GFP and YFP tags, the RFP tag has a major im-
pact on the behavior of WT-hSOD1, causing the protein
to form a single large round inclusion-like structure in the
cytosol that does not diffuse out of permeabilized cells
[15]. Similarly, we observed that WT-mSod1 fused to RFP
also produced inclusions that were saponin resistant
whether expressed alone or in combination with other
YFP tagged proteins (Additional file 1: Figures S1 and S2).
We have more recently determined that WT-hSOD1:RFP
forms inclusions because RFP has a high propensity to
dimerize and when paired with WT-hSOD1 the fusion
molecule becomes bivalent with an ability to form net-
works of interactions between molecules [23]. However,when RFP is fused to mutant hSOD1, then the inherent
propensity of the mutant hSOD1 to aggregate becomes
the primary force in behavior and inclusions formed by
mutant SOD1 fused to RFP produce multiple small inclu-
sions that ring the nucleus; these inclusions are identical
in morphology to inclusions formed by mutant SOD1
fused to YFP [23]. Thus, in the present study, we used a
paradigm in which G86R-mSod1 was fused to RFP and
co-expressed with WT-hSOD1 or WT-mSod1 fused to
YFP. Similar to WT-hSOD1, WT-mSod1 fused to YFP
showed a diffuse distribution and all of the fluorescence
was released by saponin treatment (Figure 2). Similar to
G85R-hSOD1 [23], G86R-mSod1 fused to either RFP or
YFP formed multiple small inclusions that were located
near the nucleus and resistant to release by saponin
(Figure 3). An important element in these studies to note
is that the RFP protein is much brighter than the YFP pro-
tein and thus the exposure times were adjusted to capture
the images at equivalent intensities. Typically, images of
RFP fluorescence were captured with exposures of 1/200
to 1/300 seconds whereas exposures of YFP fluorescence
were typically 1/20 to 1/30 seconds; extended to up to 1/2
to 1/3 seconds in some cases. We observed that exposure
times of up to 1/2 to 1/3 seconds in the YFP channel were
possible, with minimal bled-through of RFP into the YFP
channel (see Figure 3A column 3, row 2). Collectively,
these findings indicate that WT and mutant mSod1 be-
have similarly to WT and mutant hSOD1 in terms of pro-
pensity to aggregate.
In co-transfection experiments, we observed that inclu-
sions formed by G86R-mSod1:RFP contained little if any
WT-hSOD1:YFP within the aggregates that remained after
Figure 2 Fusions of WT-mSod1 with YFP are fully soluble. WT-mSod1:YFP proteins were expressed in CHO cells for 24 h. Cells were fixed
directly or treated with 0.1% Saponin prior fixation. Cells were immunostained with DAPI to allow visualization of cells nuclei. Note the camera
exposure times used to capture YFP images were recorded as indicated in the figure. For this figure and the relevant figures that follow, the
images shown are representative of 3 independent experiments.
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YFP appeared to be tightly bound to G85R-mSod1:RFP in-
clusion (Figure 4B). To assess whether human and mouse
SOD1 were by some manner unable to form intermingled
inclusions, we co-expressed G86R-mSod1:RFP with G85R-
hSOD1:YFP, finding that the mutant human protein
formed co-mingled inclusions with the mutant mouse pro-
tein (Figure 5A). The degree of co-mingling was similar
to what was observed when G86R-mSod1:RFP was co-
expressed with G86R-mSod1:YFP (Figure 5B). Notably, in
our assessment of the images we generally observed an all
or none response; meaning that in cells in which both pro-
teins were over-expressed either all of protein co-localized
or none co-localized. Although such data are easily quanti-
fied, the outcome does not produce a range of values and
thus it was unnecessary to tabulate quantified data (Table 1
provides a summary of the observed data). In the context
of these observations, the weak interaction between WT-
hSOD1:YFP and G86R-mSod1:RFP is indicative of some
degree of incompatibility between these proteins in gener-
ating aggregates.
Role of normal dimeric interactions in mutant SOD1
aggregation
Misfolded/aggregated forms of mutant SOD1 selectively
react with antibodies raised against sequences that are
normally inaccessible due to location within the dimer
interface [15,24]. To determine whether disrupting the
dimerization of WT-hSOD1 or WT-mSod1 may affect
interaction with misfolded mutant SOD1, we utilizedexperimental mutations known to monomerize SOD1
(SOD1-F50E/G51E; [25,26]) . To confirm that the WT
monomers of SOD1 (termed SOD1mon) can no longer
form dimeric interactions with native SOD1, we gener-
ated a series of split-luciferase reporter constructs [27]
in which the WT monomer of hSOD1 (WT-hSOD1-
mon) or native WT-SOD1 was fused to the N-terminal
or C-terminal half of humanized Gaussia luciferase
(Figure 6). As expected, co-expression of WT-SOD1 fused
to the N-terminal half of luciferase (L1) with WT-SOD1
fused to the C-terminal half of luciferase (L2) produced
high levels of luciferase activity as the homodimerization
of WT-SOD1 brought the two domains of luciferase in
close enough proximity to reconstitute enzymatic activity
(Figure 6). Also as expected, when WT-hSOD1mon was
fused to L1 and L2 domains and co-transfected, then
much less luciferase activity was detected (Figure 6). For
this latter pair of constructs, the level of activity was simi-
lar to what was detected in cells expressing the two do-
mains of luciferase alone (Figure 6; L1/L2). Similarly, very
low levels of activity were detected by any combination of
WT-hSOD1mon and WT-hSOD1 fusions to L1 or L2
(Figure 6). Immunoblots of cells transfected with the same
constructs used for luciferase assay demonstrated rela-
tively equal expression of the WT-hSOD1 and WT-
hSOD1mon fusion constructs (Additional file 1: Figure
S3). These findings indicate that the introduction of the
EE mutations at residues 50/51 of SOD1 produces a vari-
ant of SOD1 that is unable to homodimerize with itself or
heterodimerize with native WT-SOD1.
Figure 3 G86R-mSod1 fused with either RFP or YFP forms saponin-resistant inclusions. (A) G86R-mSod1:RFP and (B) G86R-mSod1:YFP
proteins were expressed in CHO cells for 24 h. Cells were fixed directly or treated with 0.1% Saponin prior fixation. Cells were immunostained
with DAPI to allow visualization of cells nuclei. Note the camera exposure times used to capture RFP and YFP images were recorded as indicated
in the figure. Digitally enlarged insets are shown to the right.
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sions of WT-hSOD1 and mSod1 affected the aggregation
of G85R-hSOD1 and G86R-mSod1 in co-transfection
studies. Interestingly, compared to native WT, we found
that monomeric WT mouse and human SOD1 proteins
were highly prone to form detergent insoluble complexes
(Figure 7A, P2 fraction; aggregation index similar to A4V-
hSOD1 at 48 hours). When the WT monomer of hSOD1
(WT-hSOD1mon) was co-expressed with G85R-hSOD1,we observed a decrease in the levels of insoluble mutant
SOD1 that accumulated in 24 hours (Figure 7A). This out-
come was similar to what we previously observed with na-
tive WT-hSOD1 when co-expressed with G85R-hSOD1
[19]. Interestingly, in these co-transfections, the levels of
highly insoluble WT-hSOD1mon were also significantly de-
creased when co-expressed with G85R-hSOD1 (Figure 7A).
Co-expression of WT-hSOD1mon with the G86R-mSod1
mutant for 24 h also significantly reduced the aggregation
Figure 4 Co-transfection of mutant mSod1 fused to RFP with YFP fusions of WT-mSod1 and WT-hSOD1. (A and B) The indicated fused
constructs were expressed in CHO cells as explained in previous figure legends and Methods. Representative images of 3 independent
experiments are shown along with digitally enlarged insets to the right.
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a significant accumulation of insoluble WT-hSOD1mon
remained detectable (Figure 7A). Co-expression of WT-
mSod1mon with G85R-hSOD1 significantly lowered the
accumulation of insoluble mutant hSOD1 over 24 hour pe-
riods (Figure 7A; lane marked with an asterisk was probed
with an antibody specific to hSOD1). Co-expression of
WT-mSod1mon with G86R-mSod1 also resulted in dimin-
ished accumulation of mutant mSod1 with a coincident re-
duction in the accumulation of insoluble WT-mSod1mon
(Figure 7A). Thus, in these experiments, which assay the
formation of detergent-insoluble complexes, we observethat a variant of WT-SOD1 that lacks the normal dimer
interface retains the ability to modulate the aggregation of
either mouse or human mutant SOD1. In this regard, the
monomerized version of WT-SOD1 from either species is
similar to what we have previously observed for native ver-
sions of these proteins [19].
To assess whether monomerized versions of WT-
SOD1 may ultimately co-aggregate with mutant SOD1,
we extended the interval post-transfection to 48 hours
before harvesting cells for detergent fractionation. By
48 hours post-transfection, co-sedimentation of detergent-
insoluble WT-hSOD1mon with G85R-hSOD1 was observed
Figure 5 Co-transfection of mutant mSod1 fused to RFP with G85R-hSOD1:YFP. The indicated fused constructs were expressed in CHO cells
as explained in previous figure legends and Methods. A) Co-transfection of vectors for G86R-mSod1:RFP with G85R-hSOD1:YFP. B) Co-transfection
of vectors for G86R-mSod1:RFP with G86R-mSod1:YFP.
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when native WT-hSOD1 is co-expressed with G85R-
hSOD1 [19]. Interestingly, in cells co-expressing WT-
hSOD1mon with G86R-mSod1 we observed a persistent
suppression of mutant mSod1 aggregation (Figure 7A).
Thus, even though WT-hSOD1mon has a higher inherent
propensity to form detergent-insoluble complexes than
native WT-hSOD1, and it is unable to dimerize, WT-
hSOD1mon showed a far greater ability to slow the aggre-
gation of G86R-mSod1 than native WT-hSOD1 (compare
Figure 1A with Figure 7A). In the reciprocal experiment,
when WT-mSod1mon was co-transfected with G85R-
hSOD1 for 48 hours post-transfection, we observed that
co-expression of WT-mSod1mon no longer inhibited ag-
gregation of G85R-hSOD1 (Figure 7A; lane marked with an
asterisk was probed with an antibody specific to hSOD1).
When WT-mSod1mon was co-expressed with G86R-
mSod1, then both proteins could be detected in detergent-
insoluble fractions, similar to when WT-hSOD1mon and
G85R-hSOD1 are co-expressed (Figure 7B). The images
shown in Figure 7A are representative of multiple experi-
ments, which were quantified to confirm the effect of WT
monomerized SOD1 of either species on the aggregation of
mutant SOD1 of either species (Figure 7B). At 24 hours
post-transfection, the cells co-expressing mutant SOD1 of
either species with WT-SOD1mon of either species ac-
cumulated less insoluble mutant SOD1 (Figure 7B). At48 hours post-transfection, the suppressive effect of WT-
SOD1mon on mutant SOD1 aggregation dissipated except
for the combination of WT-hSOD1mon with G86R-mSod1
(Figure 7B). These findings indicate that monomerized
WT-hSOD1 or mSod1 retain an ability to interact with
misfolded forms of SOD1 that generate detergent insoluble
aggregates.
In our last set of experiments, we used fusion proteins
of WT-mSod1mon and WT-hSOD1mon with YFP to
investigate further whether monomeric WT protein of ei-
ther species interacted with misfolded G86R-mSod1. WT-
hSOD1mon fusions to RFP or YFP remain soluble and
completely releasable by saponin [23]. Unexpectedly, fu-
sions of WT-mSod1mon to either RFP or YFP produced
inclusions that were saponin resistant (Figure 8). Add-
itionally, these inclusions were morphologically similar to
those produced by mutant hSOD1 fused to either tag.
When G86R-mSod1:RFP was co-expressed with WT-
hSOD1mon:YFP we observed weak interactions that were
only partially resistant to saponin; whereas the interactions
between G86R-mSod1:RFP and WT-mSod1mon:YFP were
robust and saponin resistant (Figure 9). Thus, the inher-
ently aggregation prone WT-mSod1mon readily co-
assembles with inclusions formed by G86R-mSod1:RFP
but the more soluble WT-hSOD1mon does not. These
findings indicate that monomerization of WT-hSOD1 does
not induce it to associate with misfolded G86R-mSod1.
Table 1 Comparison of assays for interactions between WT and misfolded mutant SOD1
Construct Detergent insoluble Saponin-resistant RFP or YFP tagged inclusions
WT-hSOD1 No WT-hSOD1:YFP No1
WT-hSOD1:RFP Yes1
WT-hSOD1mon Yes WT-hSOD1mon:YFP No2
WT-hSOD1mon:RFP No2
WT-mSod1 No1 WT-mSod1:YFP No
WT-mSod1:RFP Yes3
WT-mSod1mon Yes WT-mSod1mon:YFP Yes
WT-mSod1mon:RFP Yes
G86R-mSod1 Yes G86R-mSod1:YFP Yes
G86R-mSod1:RFP Yes
WT-mSod1 ? WT-mSod1:YFP Yes
+ +
G86R-mSod1 Yes 48 hr G86R-mSod1:RFP Yes
WT-mSod1mon Yes 48 hr WT-mSod1mon:YFP Yes
+ +
G86R-mSod1 Yes 48 hr G86R-mSod1:RFP Yes
WT-hSOD1 No 48 hr WT-hSOD1:YFP No
+ +
G86R-mSod1 Yes 48 hr G86R-mSod1:RFP Yes
WT-hSOD1mon Yes 48 hr WT-hSOD1mon:YFP No
+ +
G86R-mSod1 Reduced 48 hr G86R mSod1:RFP Yes
G85R-hSOD1 Yes G85R-hSOD1:YFP Yes2
G85R-hSOD1:RFP Yes2
WT-hSOD1 Yes 48 hr1 WT-hSOD1:YFP No2
+ +
G85R-hSOD1 Yes 48 hr1 G85R-hSOD1:RFP Yes2
WT-hSOD1mon Yes 48 hr WT-hSOD1mon:YFP No2
+ +
G85R-hSOD1 Yes 48 hr G85R-hSOD1:RFP Yes2
WT-mSod1 ? WT-mSod1:YFP No4
+ +
G85R-hSOD1 Yes 48 hr G85R-hSOD1:RFP Yes4
WT-mSod1mon ? WT-mSod1mon:YFP Yes5
+ +
G85R-hSOD1 Yes 48 hr G85R-hSOD1:RFP Yes5
1data from Prudencio et al. [19]; 2data from Qualls et al. [23]; 3Additional file 1: Figure S1; 4Additional file 1: Figure S4; 5Additional file 1: Figure S6.
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In the present study, we have used cell culture models of
mutant SOD1 aggregation to examine interactions between
G86R-mSod1 and human SOD1. To conduct these investi-
gations, we used two approaches that offer different ways of
detecting SOD1 misfolding. In studies that assess the forma-
tion of detergent-insoluble complexes by untagged SOD1,
we observed that native hSOD1 does not co-aggregate withG86R-mSod1. In experiments to visualize interactions be-
tween misfolded G86R-mSod1 and WT-hSOD1, we ob-
served that as compared to WT-mSod1 fusion proteins,
WT-hSOD1 fusion proteins did not readily interact with
G86R-mSod1 inclusions. Despite some noted incongru-
ities in the data as described below (summarized in
Table 1), these findings are consistent with the idea that
misfolded mutant mSod1 has a low potential to template
Figure 6 Mutations at residues F50E/G51E of SOD1 produces a variant of SOD1 that is unable to dimerize with itself or heterodimerize
with native WT-hSOD1 subunits. CHO cells were transiently transfected with indicated split luciferase constructs (illustration) and as explained
in Methods. A coelenterazine assay was used in order to demonstrate the luciferase activity of the split luciferase constructs. Each assay was
repeated at least 3 times and luminescence values were quantified. For each independent experiment, the values were normalized to the value
obtained when fusions of each segment of Gluc fused to WT-hSOD1 were co-transfected.
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in interpreting prior studies that demonstrated high levels
of WT-hSOD1 co-expressed with G86R-mSod1 had no ef-
fect on disease course in transgenic mice [13].
WT and mutant SOD1 interactions within detergent-
insoluble aggregates and cellular inclusions
Previous studies of transgenic mice have observed that
when WT-hSOD1 proteins were overexpressed with mu-
tant hSOD1, then the age at which mice developed disease
phenotypes was dramatically accelerated [7-11]. Import-
antly, these studies have clearly demonstrated that when
WT human SOD1 is co-expressed with fALS mutants of
SOD1 that are C-terminally truncated, then WT protein
can be detected in detergent-insoluble complexes as co-
sedimenting with misfolded mutant SOD1 [7,11]. Overall,
these studies suggest that mutant SOD1 may be able to
template misfolding of WT-hSOD1, inducing the latter
protein to acquire the misfolded conformation of mutant
SOD1.
In cell culture models of mutant SOD1 aggregation,
we have previously demonstrated that co-expression
of WT-hSOD1 transiently inhibits the aggregation ofG85R-hSOD1 (24 hours following transfection) but ul-
timately, at 48 hours after transfection, co-sedimentation
of WT-hSOD1 with G85R-hSOD1 in detergent-insoluble
complexes was observed [19]. In co-transfections of G85R-
hSOD1 with WT-mSod1 we could not discern whether
WT-mSod1 ultimately co-sedimented with G85R-hSOD1
because these proteins essentially co-migrate in SDS-
PAGE [19]. However, in co-transfections of WT-mSod1
with other mutants (A4V and G93A of hSOD1) it was very
clear that WT-mSod1 did not form co-sedimenting com-
plexes with the human mutant proteins [19]. In the course
of our analysis of interactions between human and mouse
SOD1 using fluorescent fusion proteins, looking at all pos-
sible combinations, we noted that WT-mSod1:YFP did not
co-aggregate with G85R-hSOD1:RFP (Additional file 1:
Figure S4). Collectively, these studies are consistent with
the idea that native WT-mSod1 does not readily interact
with misfolded forms of G85R-hSOD1; these findings may
provide an explanation for why deleting mSod1 in mice ex-
pressing G85R-hSOD1 had no obvious effect on disease
course [12].
The present study was prompted by the observation
by Audet and colleagues in which co-expression of WT-
Figure 7 The introduction of experimental mutations that monomerize WT-SOD1 produce varied effects on interactions with mutant
SOD1. A) Immunoblots of detergent-insoluble (P2) and soluble (S1) fractions of HEK293FT cells transfected with mouse and/or human SOD1
constructs for 24 (left panels) or 48 (right panels) hours. Blots were probed with an antibody that recognizes both mouse and human SOD1
proteins. Asterisk denotes probing with an antibody that is specific against human SOD1 protein. B) Quantification of the relative aggregation
propensity, as described in Figure 1, for cells transfected for 24 (black bars) or 48 (white bars) hours. Statistical analyses was performed to establish
whether the measured amount of insoluble mutant SOD1 in cells expressing only G85R-hSOD1, or only G86R-mSod1, differed from the amount
that became insoluble when either was co-expressed with monomerized variants of mSod1 and hSOD1. Explanations for notations on the graph
are as follows. The levels of insoluble G85R-hSOD1 in cells expressing only the mutant SOD1 were significantly (p≤ 0.05) higher than in cells
co-transfected with WT-hSOD1mon (hWTmon) at 24 hrs (a) and 48 hrs (b) or WT-mSod1mon (mWTmon) at 48 hrs (b). The level of G86R-mSod1
in cells expressing only mutant SOD1 were significantly (p≤ 0.05) higher than in cells co-transfected with WT-hSOD1mon or WT-mSod1mon at
24 hrs (c) or WT-hSOD1 at 48 hrs (d). Bars represent mean ± SEM.
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G86R-mSod1 develop paralysis [13]. Using a biochemical
assay for aggregation in an established cell model, we
found no evidence that native WT-hSOD1 co-sediments
with G86R-mSod1 in detergent-insoluble complexes. Si-
milarly, using fluorescently tagged SOD1 constructs to
visualize aggregation, we observed that inclusions formed
by G86R-mSod1:RFP contain little if any WT-hSOD1:YFP;
whereas WT-mSod1:YFP was readily incorporated into
these structures. Together, these findings are consistentwith the idea that native WT-hSOD1 has a low propensity
to be induced to misfold by G86R.
However, the strength of the data from examination of
RFP and YFP tagged variants of SOD1 is undermined by a
number of incongruent observations (Table 1). The pri-
mary undermining observation is that WT-hSOD1 fused
to YFP does not robustly co-deposit with inclusions formed
by G85R-hSOD1 fused to RFP [23] (Table 1). Based on co-
transfection studies of untagged WT and G85R-hSOD1
[19], we would have predicted WT-hSOD1:YFP would co-
Figure 8 WT-mSod1mon fused to RFP or YFP forms saponin-resistant inclusions. The indicated fused constructs were expressed in CHO
cells as explained in previous figure legends and Methods.
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be discounted by our prior work that has demonstrated
that the generation of detergent insoluble complexes does
not necessarily equate to inclusion formation [15]. An-
other troublesome observation was that inclusions formed
by G86R-mSod1:YFP could capture monomeric variants
of WT hSOD1 fused to RFP (Table 1; Additional file 1:
Figure S5). WT-hSOD1mon:RFP on its own appears as a
diffusely distributed protein that is released by saponin,
but does associate with inclusions formed by mutant
hSOD1 fused to YFP including the G85R mutant of
hSOD1 [23]. In multiple combinations of co-expression of
fluorescently tagged proteins (Table 1), the G85R variant
of hSOD1 and the G86R variant of mSod1 show similar
abilities to interact with WT human and mouse SOD1
proteins. The main distinguishing feature was that WT-
mSod1:YFP readily co-deposited in inclusions formed
by G86R-mSod1:RFP, providing a clear example in which
homo-specific interactions were favored. Although these
incongruities in the data diminish the conclusiveness of
this portion of the study, the data overall are consistent
with the hypothesis that native WT-hSOD1 does not read-
ily interact with misfolded mutant mouse Sod1.Role of dimer formation in mouse and human SOD1
interactions
Experimental conversion of SOD1 from a dimeric to a
monomeric enzyme by the mutation of residues 50
(Phe) and 51 (Gly) to Glu was first described by Bertini
et al. [25,26]. It is thought that the introduction charged
residues at these sites produces a repulsive effect as the
two monomers of SOD1 attempt to align as a homodi-
meric enzymes. These monomeric enzymes retain activ-
ity and crystal structures of this experimental variant
have demonstrated that the proteins can fold into a near
normal conformation [26]. Thus, the engineered mono-
mer of SOD1 is thought to be WT-like in its properties.
To confirm that the mutations that monomerize SOD1
inhibit interactions between subunits, we developed a split-
luciferase assay. As predicted, the monomerization muta-
tions in WT-hSOD1 produced a protein that failed to
homodimerize. An important consideration in our studies
of interactions between mutant SOD1 and monomerized
WT-SOD1 was that the mutant variants possessed intact
dimer interfaces and thus the effect of the engineered
monomer mutations could have been less robust. However,
data from the split luciferase assay demonstrated that
Figure 9 Co-transfection of G86R-mSod1:RFP with WT-hSOD1mon and WT-mSod1mon fused to YFP. (A and B) The indicated fused
constructs were expressed in CHO cells as explained in previous figure legends and Methods. WT-hSOD1mon weakly interacts with G86R-mSod1:
RFP inclusions whereas WT-mSod1mon shows a strong saponin resistant interaction.
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ciently dimerize with WT-SOD1. Thus, we are confident
that monomerized WT-hSOD1 variants were behaving as
monomeric proteins.
Our data demonstrate that, when over-expressed,
untagged versions of both WT-hSOD1mon and WT-
mSod1mon were prone to form detergent insoluble com-
plexes. Thus, in both the mouse and human proteins, the
monomerizing mutations impacted the tendency of these
proteins to aggregate. This finding fits with data fromseveral studies that have suggested loss of dimerization is
a key step in the aggregation of SOD1 [28-32]. However,
the behavior of RFP and YFP tagged monomeric variants
of human and mouse SOD1 produced a more complicated
picture. We show here that monomeric variants of WT-
mSod1 produced saponin resistant inclusions; whereas the
monomerized WT-hSOD1:YFP proteins have been shown
to exhibit properties of a fully soluble protein [23]. It ap-
pears that the mutations that monomerize WT-mSod1
had a more profound impact on structure than the same
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form inclusions. Additionally, it is interesting that the
untagged version of WT-hSOD1mon is more prone to
adopt detergent insoluble complexes, but a fusion of WT-
hSOD1mon to YFP exhibits properties of a soluble protein
[23] (Table 1). Notably, we have previously observed
that formation of detergent-insoluble complexes does
not necessarily equate to formation of inclusions; WT-
hSOD1:YFP is generally more prone to lose solubility
in non-ionic detergent without producing inclusions
[15]. For WT-hSOD1 we conclude that the mutations
that monomerize the protein may heighten propensity
to aggregate in the presence of non-ionic detergents,
but it does seem that the protein is so badly folded that
it easily forms the large aggregates that produce visible
inclusions.
From transfection of untagged SOD1 variants, we ob-
served that monomerization of WT-hSOD1 had no ob-
vious effect on its interactions or influence over the
aggregation of G85R-hSOD1 into detergent-insoluble com-
plexes. Co-expression of WT-hSOD1mon with G85R-
hSOD1 produced effects similar to what we have previously
reported in co-transfection of native WT-hSOD1 with mu-
tant hSOD1 [19]: initially in 24 hours we observed an inhib-
ition of mutant SOD1 aggregation, but at 48 hours we
observe both proteins co-sedimenting in the detergent-
insoluble fractions (see Figure 7). Similarly, we observed
that WT-mSod1mon transiently inhibited the formation of
detergent-insoluble complexes by either G85R-hSOD1 or
G86R-mSod1. At 48 hours following transfection, we could
clearly discern that WT-hSOD1mon was induced to form
co-sedimenting complexes with G85R-hSOD1 (Table 1),
but in cells co-expressing WT-hSOD1mon and G86R-
mSod1 there was significant reduction in level of aggre-
gated G86R-mSod1 (see Figure 7). For some combinations
of co-transfections, it was more difficult to tell whether
both proteins co-sedimented because of co-migration in
SDS-PAGE. For example, in co-expression of WT-mSod1
with G85R-hSOD1, we were able to confirm the presence
of G85R-hSOD1 in the detergent-insoluble fraction using a
human specific SOD1 antibody but we were unable to
distinguish whether WT-mSod1 was also present (see
Figure 7). Overall, in those cases in which we could make
definitive observations, our study of the formation of deter-
gent insoluble complexes indicates that monomerization
of WT-SOD1 of either species did not abrogate its ability
to make homo-specific interactions with mutant SOD1
(mouse to mouse or human to human). This finding indi-
cates normal dimeric interactions are not required to in-
duce the co-aggregation of mutant SOD1 with WT-like
protein. Moreover, for both the native fusion proteins of
WT-hSOD1or mSod1 and the monomeric variants we ob-
serve a preference for homo-specific interactions over
hetero-specific interactions.In our studies of fluorescently-tagged proteins, we ob-
served instances of agreement with our biochemical assays
as well as instances of incongruity. In co-expression studies
of G86R-mSod1:RFP with WT-hSOD1mon:YFP and WT-
mSod1mon:YFP, we observed a preferential recruitment of
the WT mouse fusion protein into the inclusions; a finding
that corroborated the biochemical assays. However, the ap-
parent selectivity of mouse for mouse was offset by our pre-
vious observation that WT-hSOD1mon:YFP did not readily
incorporate into inclusions formed by G85R-hSOD1:RFP
[23] (Table 1). Moreover, we have observed that WT-
hSOD1mon:RFP, which behaves as a soluble protein, read-
ily interacts with inclusions formed by mutant SOD1 fused
to YFP [23] (Table 1). WT-hSOD1mon:RFP also interacts
with inclusions formed by G86R-mSod1:YFP (Additional
file 1: Figure S5); a finding that is somewhat incongruent
with our biochemical data. Thus, overall, the data gener-
ated by studies with fluorescently tagged variants of human
and mouse SOD1 partially corroborate the biochemical.
Conclusions
In the present study, we have used both biochemical and
visual assays to determine the degree to which a variant of
mouse SOD1 carrying the fALS mutation (G85R/G86R) in-
teracts with WT-hSOD1. We have also examined the role
of normal dimeric interactions between SOD1 subunits in
the generation of aggregates that contain both proteins.
Our biochemical assays for acquisition of detergent-
insolubility, in which untagged SOD1 was over-expressed,
indicate that mutant mouse SOD1 preferentially interacts
with WT mouse SOD1 and conversely mutant human
SOD1 preferentially interacts with WT human SOD1.
Mutations that monomerize the WT protein do not signifi-
cantly diminish these interactions. Thus, for homo-specific
interactions in the generation of detergent-insoluble com-
plexes, the normal dimeric interaction is not required. Our
visual assays of aggregation and co-aggregation, using YFP
tagged proteins, paint a more complex picture possibly be-
cause the fluorescent tag that was used to track the protein
was not completely benign [23] (Table 1). The most clear-
cut observation that could be made was that G86R-mSod1
readily interacts with WT-mSod1 whether native or mono-
merized. Overall, the data are consistent with the hypothesis
that increasing the level of WT-hSOD1 in mice expressing
G86R-mSod1 does not accelerate the onset of disease, as
observed by Audet et al. [13], because the human protein
does not readily interact with misfolded mouse protein.
Additional file
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inclusions. Figure S2. Additional comparative data for WT-mSod1:RFP
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